Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02770092 · ClinicalTrials.gov registry record · NA
CHF COPD Sip Feed Anabolic Response
A NA study, sponsored by Texas A&M University.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT02770092 is a NA study that has completed, run by Texas A&M University. The registered enrollment target is 90 participants.
The verdict
NCT02770092, a NA study, has completed, sponsored by Texas A&M University.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
Weight loss commonly occurs in patients with chronic heart failure (CHF) and chronic obstructive pulmonary disorder (COPD), negatively influencing their quality of life, treatment response and survival. Loss of muscle protein is generally a central component of weight loss in CHF and COPD patients, but patients also have reductions in fat mass and bone density, independent of the severity of the disease state. The purpose of this study is to provide detailed insight in disease related gut function by obtaining information on gut permeability, digestion and absorption of glucose, fat and protein in CHF and COPD patients compared to matched healthy controls. This will provide required information that is necessary to implement new strategies to develop optimal nutritional regimen in CHF and COPD.
Interventions
- OTHER sip feeding with stable isotope infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2016-02-10 |
| Est. Completion | 2018-05-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02770092
The ClinicalTrials.gov registry entry for NCT02770092 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas A&M University, which has 95 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sip feeding with stable isotope infusion is the first listed.
NCT02770092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02770092 about?
NCT02770092 is a clinical study titled "CHF COPD Sip Feed Anabolic Response". Weight loss commonly occurs in patients with chronic heart failure (CHF) and chronic obstructive pulmonary disorder (COPD), negatively influencing their quality of life, treatment response and survival. Loss of muscle protein is generally a central component of weight loss in CHF and COPD patients, ...
What is the current status of trial NCT02770092?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2016-02-10. Estimated completion is 2018-05-15.
What interventions are being tested in trial NCT02770092?
The interventions under investigation include: sip feeding with stable isotope infusion (OTHER).
Who is sponsoring clinical trial NCT02770092?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.